Actively Recruiting
Markers of Osteoporosis in Cystic Fibrosis
Led by University of Texas Southwestern Medical Center · Updated on 2026-05-05
100
Participants Needed
1
Research Sites
304 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Main Study Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection. Denosumab (Prolia) Sub study Approximately 10 adult subjects with CF who participated in the main study and have results indicating bone disease will receive treatment with Denosumab for up to 5 years. They will be asked to return for repeat DEXA scans, micro CT, blood collection, and documenting of any adverse events.
CONDITIONS
Official Title
Markers of Osteoporosis in Cystic Fibrosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must have cystic fibrosis diagnosis confirmed by sweat test or genotype analysis
- Ability to read and write in English
You will not qualify if you...
- No cystic fibrosis diagnosis
- Men or women without osteoporosis
- Younger than 18 years of age
- Unwilling to return annually for study visits for up to 5 years
- Unwilling or medically unable to take denosumab
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
Actively Recruiting
Research Team
A
Ashley Keller
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here